Evidence map›Paper›PMID 42244082›Full record

ArticleJournal of the International Association of Providers of AIDS Care

Clinic and Provider Innovations to Improve Tuberculosis Infection Screening and Preventive Therapy Uptake in Brazil: Qualitative Findings From the PREVINE-TB Study.

Deanna Kerrigan, Lelia H Chaisson, Paula Travassos, Betina Durovni, Valeria Saraceni, Solange Cavalcante, Marcelo Cordeiro-Santos, Renata Spener-Gomes, Alexandra Brito de Souza, Sumire Sakabe and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the International Association of Providers of AIDS Care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Deanna KerriganDepartment of Health, Behavior, Society and Policy, Rutgers University School of Public Health, Piscataway, NJ, USA.ORCID 0000-0001-7401-9159
Lelia H ChaissonUCSF Center for Tuberculosis and UCSF Institute for Global Health Sciences, University of California, San Francisco, CA, USA.
Paula TravassosVigilancia em Saúde, Secretaria Municipal de Saúde, Rio de Janeiro, RJ, Brazil.
Betina DurovniVigilancia em Saúde, Secretaria Municipal de Saúde, Rio de Janeiro, RJ, Brazil.
Valeria SaraceniVigilancia em Saúde, Secretaria Municipal de Saúde, Rio de Janeiro, RJ, Brazil.
Solange CavalcanteVigilancia em Saúde, Secretaria Municipal de Saúde, Rio de Janeiro, RJ, Brazil.
Marcelo Cordeiro-SantosGerência de Micobacteriologia, Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, AM, Brazil.
Renata Spener-GomesGerência de Micobacteriologia, Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, AM, Brazil.
Alexandra Brito de SouzaGerência de Micobacteriologia, Fundação de Medicina Tropical Dr Heitor Vieira Dourado, Manaus, AM, Brazil.
Sumire SakabeCentro de Referência e Treinamento DST/AIDS, Secretaria de Estado da Saúde de São Paulo, São Paulo, SP, Brazil.
Roberta TrefiglioCentro de Referência e Treinamento DST/AIDS, Secretaria de Estado da Saúde de São Paulo, São Paulo, SP, Brazil.
José Valdez Ramalho MadrugaCentro de Referência e Treinamento DST/AIDS, Secretaria de Estado da Saúde de São Paulo, São Paulo, SP, Brazil.
Silvia CohnDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lia S Da Silva KerriganDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Isadora SallesDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Barbara CastroCentro de Estudos Estratégicos, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Danielle Portella FerreiraCentro de Estudos Estratégicos, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Christopher J HoffmannDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jonathan E GolubDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionDiagnosing and treating tuberculosis (TB) infection are critical to reducing TB mortality among people with HIV (PLHIV). Blood-based screening using QuantiFERON-TB Gold Plus (QFT+) and shorter-course TB preventive therapy (TPT) regimens such as 3-month weekly isoniazid and rifapentine (3HP) hold promise to improve TB outcomes.MethodsWe conducted 38 qualitative interviews to explore implementation challenges and solutions related to QFT+ use and TPT uptake among PLHIV participating in the PREVINE-TB study in Brazil and utilized thematic analysis.ResultsClinic and provider implementation innovations and examples of positive deviance helped explain quantitative differences in QFT+ use and TPT uptake between cities including predetermination of eligible patients for QFT+ screening based on nurse review of electronic medical records, specialized TB clinics, the use of TPT Champions, and digital communication.ConclusionsClinic and provider innovations can support QFT+ use and TPT uptake to improve TB outcomes, including in the context of health systems challenges.

Indexed as

Adherence InterventionsAntitubercular AgentsHIV InfectionsMass ScreeningTuberculosisAdultBrazilFemaleHumansInterferon-gamma Release TestsIsoniazidMaleQualitative ResearchRifampinAntitubercular AgentsIsoniazidRifampinrifapentineHIV/AIDSimplementation scienceintegrated careTBtreatment adherencetuberculosis

Identifiers

PMID42244082
PMCPMC13237461

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.